---
title: "Morgan Stanley: WuXi AppTec is expected to exceed the full-year revenue growth guidance, maintaining an \"Overweight\" rating"
description: "Morgan Stanley released a research report stating that WuXi AppTec (02359) reported a 15.3% year-on-year increase in revenue for the third quarter to RMB 12.1 billion, and a 53.3% increase in net prof"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/262854761.md"
published_at: "2025-10-27T09:27:06.000Z"
---

# Morgan Stanley: WuXi AppTec is expected to exceed the full-year revenue growth guidance, maintaining an "Overweight" rating

> Morgan Stanley released a research report stating that WuXi AppTec (02359) reported a 15.3% year-on-year increase in revenue for the third quarter to RMB 12.1 billion, and a 53.3% increase in net profit to RMB 3.515 billion. Adjusted net profit under non-International Financial Reporting Standards rose 42% to RMB 4.22 billion, exceeding the bank's expectations. Among these, revenue from chemical, testing, and biological businesses grew by 23%, 2%, and 6% year-on-year, respectively. The bank also believes that now is an appropriate time to purchase shares of WuXi AppTec, as the stock's forecast price-to-earnings ratio for the fiscal year 2026 is about 20 times, lower than the industry median of 26 times; it has given a "buy" rating with a target price of RMB 105 for A-shares. The company has raised its full-year revenue growth guidance for continuing operations from 13%-17% to 17%-18%. The bank believes this adjustment is similar to the approach taken in the first half of this year, with a relatively conservative increase in the upper limit and a significant increase of 4 percentage points in the lower limit. The company's revenue for the first nine months has accumulated a year-on-year growth of 22.5%, and the bank believes its full-year performance is expected to meet or even exceed the guidance

According to the Zhitong Finance APP, Morgan Stanley released a research report stating that WuXi AppTec (02359, 603259.SH) reported a 15.3% year-on-year increase in revenue for the third quarter to RMB 12.1 billion, and a 53.3% increase in net profit to RMB 3.515 billion. Adjusted net profit under non-International Financial Reporting Standards rose 42% to RMB 4.22 billion, exceeding the bank's expectations. Among them, revenue from chemical, testing, and biological businesses grew by 23%, 2%, and 6% year-on-year, respectively. The bank also believes that now is a suitable time to purchase shares of WuXi AppTec, as the stock's forecast price-to-earnings ratio for the fiscal year 2026 is about 20 times, lower than the industry median of 26 times; it has given a "buy" rating with a target price of RMB 105 for A-shares.

The company has raised its full-year revenue growth guidance for continuing operations from 13%-17% to 17%-18%. The bank believes that this adjustment is similar to the approach taken in the first half of this year, with a relatively conservative increase in the upper limit and a significant increase of 4 percentage points in the lower limit. The company's revenue for the first nine months has accumulated a year-on-year growth of 22.5%, and the bank believes that its full-year performance is expected to meet or even exceed the guidance

### Related Stocks

- [603259.CN - WuXi AppTec](https://longbridge.com/en/quote/603259.CN.md)
- [02359.HK - WUXI APPTEC](https://longbridge.com/en/quote/02359.HK.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| 早盘趋势｜药明康德缩量探底，消息面要驱动短线变盘？ | 昨日下午，药明康德 A/H 两地联动，股价低开震荡，尾盘试探阶段性新低，资金谨慎防守。港股医药板块依然低迷，近期消息面少有亮点，市场更关注国内仿制药政策推进和新冠用药销售情况，但药明康德暂无新公告刺激。 日前公司曾发表与海外头部药企合作进展 | [Link](https://longbridge.com/en/news/270592150.md) |
| 药明康德在最新的演讲中突出了其全球 CRDMO 增长和创新平台 | 药明康德有限公司在 CRDMO 领域展示了其商业战略和业绩，强调了强大的产品管线，截至 2025 年第三季度，拥有 2,889 个临床前和第一阶段分子，374 个第二阶段分子，以及 87 个第三阶段分子。公司报告 2025 年调整后的非国际 | [Link](https://longbridge.com/en/news/272617439.md) |
| 新春伊始，如何看待人民币升值？ | 人民币汇率在 2023 年 2 月 12 日突破 6.9 关口，创 33 个月新高。尽管一些国家指责人民币汇率低估影响贸易，但市场对人民币资产的看法已转变，开始关注哪些中国资产值得投资。美元走弱是人民币升值的背景之一，但人民币升值的节奏还需 | [Link](https://longbridge.com/en/news/276026949.md) |
| 罗致恒富｜10-K：2025 财年营收 53.79 亿美元超过预期 |  | [Link](https://longbridge.com/en/news/275941343.md) |
| Netgear｜10-K：2025 财年营收 7 亿美元超过预期 |  | [Link](https://longbridge.com/en/news/275944453.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.